All posts by: Michael Zand

USRM Chief Science Officer Featured in Powerful Stem Cell Docuseries – PR Newswire (press release)

Digital JournalUSRM Chief Science Officer Featured in Powerful Stem Cell DocuseriesPR Newswire (press release)SUNRISE, Fla., Jan. 24, 2018 /PRNewswire/ — U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based ste… Continue reading

Subcutaneous and Sublingual Immunotherapy Effectiveness in Pediatric Asthma – Pulmonology Advisor

Pulmonology AdvisorSubcutaneous and Sublingual Immunotherapy Effectiveness in Pediatric AsthmaPulmonology AdvisorChildren with allergic asthma who are treated with subcutaneous immunotherapy (SCIT) may not experience a significant change in symptoms co… Continue reading

Paragon expansion to address ‘deficit in gene therapy CDMO capacity’ – BioPharma-Reporter.com

CRISPR patent dispute: Broad Institute has key rights revoked in Europe – Genetic Literacy Project

Genetic Literacy ProjectCRISPR patent dispute: Broad Institute has key rights revoked in EuropeGenetic Literacy ProjectA decision from the European Patent Office (EPO) has put the Broad Institute in Cambridge, Massachusetts, on shaky ground with its in… Continue reading

CD34 protein found to be much more than a stem cell marker – News-Medical.net

CD34 protein found to be much more than a stem cell markerNews-Medical.netA protein used to identify blood-forming cells is much more than a mere surface marker. A KAUST study shows that this protein, known as CD34, also plays a key role in binding adh… Continue reading

Part 3: The central role of stem cells and telomeres in the aging process – Long Long Life (blog)

Long Long Life (blog)Part 3: The central role of stem cells and telomeres in the aging processLong Long Life (blog)Regarding skin stem cells, the role of telomere length and activity was always established from TERC-/- mice models, mice lacking the … Continue reading

Synlogic Announces Pricing of Public Offering of Common Stock – Business Wire (press release)

Synlogic Announces Pricing of Public Offering of Common StockBusiness Wire (press release)CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, to… Continue reading